A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

New research suggests that Americans' risk for developing dementia over a lifetime may be higher than previously thought.

AuTonomy 是一项随机、双盲、安慰剂对照、平行分组、多中心的 II 期临床研究，旨在评估 Posdinemab 在早期 AD 患者中的疗效和安全性。该研究已入组 523 名受试者，主要终点是 第 104 周 AD 综合评分量表 ...

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

The company placed big bets on its Alzheimer’s drug aducanumab which has so far achieved some success. Biogen is now taking the drug to phase 3 trials. Other candidates from big-named ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...

Neurologists, neurology residents and fellows, medical students, social workers, masters in administration, physician assistants, nurse practitioners, nurses and pharmacists. Additionally, Neurology ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...